Profile data is unavailable for this security.
About the company
COSCIENS Biopharma Inc. is a Canada-based life science company. The Company is developing and commercializing a diversified portfolio of products for the cosmeceutical, nutraceutical and pharmaceutical markets. The Company’s patented technologies include the Pressurized Gas eXpanded (PGX) technology, which is a technology that generates high-value yields of active ingredients from natural-based resources for use in novel cosmeceutical, nutraceutical and pharmaceutical products. The Company's two products, oat beta glucan and avenanthramides, are found in household-name cosmetic and personal care brands. These products are manufactured from the Company’s proprietary oat extraction manufacturing technology and are known for their well-documented health benefits. Its lead product, macimorelin (Macrilen; Ghryvelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD).
- Revenue in CAD (TTM)12.27m
- Net income in CAD-20.20m
- Incorporated1990
- Employees21.00
- LocationCOSCIENS Biopharma IncC/O Norton Rose Fulbright Canada Llp222 Bay Street, Suite 3000,PO Box 53TORONTO M5K 1E7CanadaCAN
- Phone+1 (418) 652-8525
- Fax+1 (418) 948-9191
- Websitehttps://www.cosciensbio.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| StageZero Life Sciences Ltd | -100.00bn | -100.00bn | 4.82m | 40.00 | -- | -- | -- | -- | -- | -- | -- | -0.1221 | -- | -- | -- | -- | -- | -135.76 | -- | -- | -- | -2.74 | -- | -246.92 | 0.0177 | -- | -- | -- | -25.12 | 55.93 | -52.53 | -- | -- | -- |
| Quest PharmaTech Inc | 0.00 | -96.59k | 6.70m | 0.00 | -- | 0.2931 | -- | -- | -0.0006 | -0.0006 | 0.00 | 0.1365 | 0.00 | -- | -- | -- | -0.398 | 10.66 | -0.4181 | 11.12 | -- | -- | -- | -- | -- | -- | 0.0415 | 0.00 | -- | -- | 40.32 | -- | -- | -- |
| Marvel Biosciences Corp | 0.00 | -2.28m | 8.62m | -- | -- | -- | -- | -- | -0.045 | -0.045 | 0.00 | -0.0635 | 0.00 | -- | -- | -- | -499.17 | -239.13 | -- | -- | -- | -- | -- | -- | -- | -4.89 | -- | -- | -- | -- | -34.02 | -- | -- | -- |
| COSCIENS Biopharma Inc | 12.27m | -20.20m | 9.30m | 21.00 | -- | 1.35 | -- | 0.7575 | -6.41 | -6.41 | 3.88 | 2.16 | 0.2678 | 1.96 | 5.18 | -- | -44.08 | -24.51 | -53.74 | -27.91 | 45.14 | 62.83 | -164.63 | -175.84 | 3.03 | -- | 0.2994 | -- | 34.22 | 78.30 | -339.28 | -- | -- | -- |
| Medicure Inc | 26.21m | -3.43m | 12.00m | 23.00 | -- | 0.6934 | -- | 0.458 | -0.3286 | -0.3286 | 2.51 | 1.66 | 0.9492 | 3.90 | 5.93 | 1,139,435.00 | -12.42 | -5.22 | -17.87 | -7.48 | 47.67 | 60.98 | -13.08 | -8.17 | 1.00 | -- | 0.0546 | -- | 0.9818 | 1.66 | -12.69 | -- | -44.35 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Goodwood, Inc.as of 30 May 2025 | 241.57k | 7.59% |
| Osaic Wealth, Inc. (Investment Management)as of 30 Sep 2025 | 50.00 | 0.00% |
| Truvestments Capital LLCas of 30 Sep 2025 | 0.00 | 0.00% |
| Morgan Stanley & Co. LLCas of 30 Sep 2025 | 0.00 | 0.00% |
| RBC Dominion Securities, Inc. (Investment Management)as of 30 Sep 2025 | 0.00 | 0.00% |
| Raymond James Financial Services Advisors, Inc.as of 30 Sep 2025 | 0.00 | 0.00% |
| G1 Execution Services LLCas of 30 Sep 2025 | 0.00 | 0.00% |
| Desjardins Securities, Inc.as of 30 Sep 2025 | 0.00 | 0.00% |
| BNP Paribas Financial Marketsas of 30 Sep 2025 | 0.00 | 0.00% |
| TD Waterhouse Canada, Inc.as of 31 Dec 2025 | 0.00 | 0.00% |
